These findings have led to a prompt therapeutic attention over whether modulation of the ACE2 activity/expression can change the clinical course of COVID-19 and whether the use of RAAS blockade will cause any difference in clinical outcome based on its modulating role of ACE2 expression/activity23. This evidence concerns the gene ACE2 and COVID-19.